Preclinical data demonstrates the ability of our first lead compound to rescue the integrity of skin cells from a patient with EB simplex and to effectively activate the required compensatory mechanisms in live skin. 

Mariposa is now in the process of developing this programme to enter clinical trials, with second generation compounds now in hit-lead discovery. 

Mariposa has developed novel proprietary reporter cell lines and screening cascades for high-throughput screening of keratin activating and keratin inhibiting compounds to discover treatments for a wide range of skin diseases.